Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma

Peking University Cancer Hospital & Institute

Status: Unknown

Conditions: Lymphoma, T-Cell, Peripheral

Treatments: Device: 18F-FDG PET/CT

Study type: Interventional

Funder types: Other

Identifiers

NCT03051568

XW-PTCL-001

Details and patient eligibility

About

The purpose of this study is to evaluate whether a semi-quantitative interpretation using the liver SUVmax as reference can better interpret 18F-FDG PET/CT and predict disease progression during chemotherapy or survival in PTCL.

Full description

In this study investigators develope a semi-quantitative interpretation using the liver SUVmax as reference to interpret 18F-FDG PET/CT. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold or new 18F-FDG avid lesions. Investigators compare the prognostic accuracy of the liver SUVmax-based criteria with the 5-PS criteria and ΔSUVmax interpretation with respect to predicting disease progression during chemotherapy or survival in PTCL. Furthermore,investigators improve the prognostic ability of interim PET/CT by comparing the results to the clinical prognostic factors.

Enrollment: 80 estimated patients

Sex: All

Ages: 12 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• newly diagnosed PTCL
• treated using an anthracycline-containing regimen
• minimal follow-up at 6 months after the completion of first-line treatment
• complete medical history and clinicopathological data

Exclusion criteria

• secondary malignant disease
• serious infection or inflammation (e.g., HIV)
• primary central nervous system lymphoma
• hepatic or renal dysfunction.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

80 participants in 1 patient group

PTCL patients with 18F-FDG PET/CT

Experimental group

Description:

18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria

Treatment:

Device: 18F-FDG PET/CT